Another Ebola case detected outside DRC's main hot spots
7 SEP - The case is in a village in Masereka health zone not far from the large city of Butembo.
Study provides data behind new MDR-TB guidance
7 SEP - Newer and repurposed drugs produced better results and fewer deaths than older treatments did.
WHO Updates Dengue Vaccine position - WER
7 SEP - In November 2017, results of a retrospective analysis of data from clinical trials, using a new serological assay, became available. The assay enabled classification of trial participants according to their dengue serostatus prior to receipt of the first vaccine dose. These data revealed an excess risk of severe dengue in seronegative vaccine recipients compared to seronegative non-vaccinated individuals, while confirming long-term protection in seropositive individuals.3 In view of these findings, SAGE provided revised recommendations in April 2018, on which this position paper is based.
Taiwan’s Annual Seasonal Influenza Mass Vaccination Program—Lessons for Pandemic Planning
7 SEP - Rapid medical countermeasure (MCM) dispensing is an important intervention during a public health emergency. In the United States, MCM planning and exercising efforts have largely focused on dispensing therapeutics, with less emphasis on mass vaccination operations that would require additional specialized staff and infrastructure. Difficulties in distributing vaccines during the 2009 H1N1 influenza pandemic highlighted the need for enhanced planning and exercising of plans for conducting mass vaccination campaigns.
In Taiwan, seasonal influenza mass vaccination campaigns are conducted annually, which both mitigate the effects of seasonal influenza and serve as functional exercises for mass vaccination operations during a pandemic. To identify lessons that can be applied to mass vaccination planning in the United States and elsewhere, we conducted an in-person observation and data review of Taiwan’s annual seasonal influenza mass vaccination efforts in October 2017.
We offer findings and recommendations for enhancing preparedness for seasonal and pandemic influenza and other public health emergencies that would require mass vaccination.
User-charges for UC get new push
6 SEP (Bangkok) - A proposal that people earning more than 100,000 baht annually be subject to co-payments of 10-20% for health services covered by the Universal Healthcare Coverage (UC) scheme has come under fire as agencies distance themselves from the idea.
This is not a drill: 5 reasons why the experts are worried about the next pandemic
6 SEP - By officially designating an unknown pathogen as a likely cause of a global outbreak, the WHO has upped the ante on the need to be better prepared. While we may not know what ‘Disease X’ is, in all probability it’s coming. Conditions are ripe for its arrival.
But are we ready? Here’s five reasons why we should answer that question carefully.
Rapid Detection Accelerates India’s Response to Nipah Outbreak
6 SEP - On May 17, 2018, almost two weeks after his brother died of febrile illness, a male patient in his mid-twenties visited a hospital in Kerala, India, with a fever. A day later, he was dead — but not before his doctors noticed his symptoms were consistent with encephalitis.Recognizing the potential danger, they immediately sent samples from the patient to the Manipal Centre for Virus Research (MCVR), followed by the National Institute of Virology (NIV) in Pune, where laboratory tests identified the cause of death as Nipah virus.
Limiting universal healthcare to those who earn less than Bt100,000 unfair, says activist
5 SEP (Thailand) - A PROMINENT health activist yesterday attacked the government over reports that it plans to provide free medical service under the universal healthcare scheme to only those earning less than Bt100,000 a year. This idea made the headlines earlier this week, causing widespread concern. The scheme currently covers more than 48 million Thais who are not covered by the social security scheme and the medical benefit programme for civil servants, state-enterprise employees and their family members.
First human trial of Lassa fever antiviral
5 SEP - Phase 1 study to assess the safety, tolerability and pharmacokinetic profile of LHF-535 in healthy volunteers. No therapy or vaccine currently approved for use in Lassa fever.
New single-dose antiviral cuts flu symptoms, viral loads
5 SEP - Baloxavir reduced flu symptoms by 1 day and reduced viral shedding.